These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 21788562)
1. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562 [TBL] [Abstract][Full Text] [Related]
2. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
3. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. Sohn HS; Kwon JW; Shin S; Kim HS; Kim H J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867 [TBL] [Abstract][Full Text] [Related]
5. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma]. Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951 [No Abstract] [Full Text] [Related]
6. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. Takeda M; Okamoto I; Nakagawa K J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683 [TBL] [Abstract][Full Text] [Related]
8. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867 [TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876 [TBL] [Abstract][Full Text] [Related]
10. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536 [TBL] [Abstract][Full Text] [Related]
11. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106 [TBL] [Abstract][Full Text] [Related]
12. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059 [TBL] [Abstract][Full Text] [Related]
13. [EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib]. Zhong W; Wang M; Li L; Xia Y; Chen M; Zhang L; Zhao J Zhongguo Fei Ai Za Zhi; 2012 Sep; 15(9):513-20. PubMed ID: 22989454 [TBL] [Abstract][Full Text] [Related]
14. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717 [TBL] [Abstract][Full Text] [Related]
15. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152 [TBL] [Abstract][Full Text] [Related]
16. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study. Kashiwabara K; Fujii S; Tsumura S; Sakamoto K J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455 [TBL] [Abstract][Full Text] [Related]
18. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Yoshida K; Yatabe Y; Park J; Ogawa S; Park JY; Shimizu J; Horio Y; Matsuo K; Mitsudomi T; Hida T J Cancer Res Clin Oncol; 2010 Apr; 136(4):527-35. PubMed ID: 19777258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]